Mizuho Maintains Outperform on WAVE Life Sciences, Raises Price Target to $27

Benzinga Newsdesk www.benzinga.com Positive 91.2%

Neg 0% Neu 0% Pos 91.2%

Mizuho analyst Salim Syed maintains WAVE Life Sciences (NASDAQ:WVE) with a Outperform and raises the price target from $22 to $27.